JP2008537778A5 - - Google Patents

Download PDF

Info

Publication number
JP2008537778A5
JP2008537778A5 JP2008504275A JP2008504275A JP2008537778A5 JP 2008537778 A5 JP2008537778 A5 JP 2008537778A5 JP 2008504275 A JP2008504275 A JP 2008504275A JP 2008504275 A JP2008504275 A JP 2008504275A JP 2008537778 A5 JP2008537778 A5 JP 2008537778A5
Authority
JP
Japan
Prior art keywords
cancer
kit according
vitamin receptor
antibody
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008504275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008537778A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/011376 external-priority patent/WO2006105141A1/en
Publication of JP2008537778A publication Critical patent/JP2008537778A/ja
Publication of JP2008537778A5 publication Critical patent/JP2008537778A5/ja
Withdrawn legal-status Critical Current

Links

JP2008504275A 2005-03-30 2006-03-30 細胞の葉酸ビタミン受容体の定量化による癌予後診断法 Withdrawn JP2008537778A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66643005P 2005-03-30 2005-03-30
PCT/US2006/011376 WO2006105141A1 (en) 2005-03-30 2006-03-30 Method for cancer prognosis using cellular folate vitamin receptor quantification

Publications (2)

Publication Number Publication Date
JP2008537778A JP2008537778A (ja) 2008-09-25
JP2008537778A5 true JP2008537778A5 (enExample) 2009-05-14

Family

ID=36754569

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008504275A Withdrawn JP2008537778A (ja) 2005-03-30 2006-03-30 細胞の葉酸ビタミン受容体の定量化による癌予後診断法

Country Status (10)

Country Link
US (1) US20090081710A1 (enExample)
EP (2) EP1864133B1 (enExample)
JP (1) JP2008537778A (enExample)
CN (1) CN101203759A (enExample)
AT (1) ATE460668T1 (enExample)
AU (1) AU2006230219A1 (enExample)
CA (1) CA2602585A1 (enExample)
DE (1) DE602006012816D1 (enExample)
RU (1) RU2007139912A (enExample)
WO (1) WO2006105141A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1389209B1 (en) 2001-04-24 2009-04-08 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
US7910594B2 (en) 2002-05-15 2011-03-22 Endocyte, Inc. Vitamin-mitomycin conjugates
AR042942A1 (es) 2003-01-27 2005-07-06 Endocyte Inc Conjugados de administracion de drogas de union de receptores de vitaminas
US20050232919A1 (en) 2004-02-12 2005-10-20 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
EP1789391B1 (en) 2004-07-23 2017-06-28 Endocyte, Inc. Bivalent linkers and conjugates thereof
CN101175757B (zh) 2005-03-16 2012-11-14 恩多塞特公司 蝶酸及其缀合物的合成和纯化
US20060239910A1 (en) 2005-04-22 2006-10-26 Morphotek Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
CN103893778A (zh) 2005-08-19 2014-07-02 恩多塞特公司 多药物配体缀合物
WO2008101231A2 (en) 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
JP5829793B2 (ja) 2007-03-14 2015-12-09 エンドサイト・インコーポレイテッドEndocyte, Inc. 結合性リガンドが結合したツブリシンの薬剤送達結合体
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
WO2009002993A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
CN101909441B (zh) 2007-10-25 2015-05-13 恩多塞特公司 微管蛋白抑制剂及其制备方法
CN104857534A (zh) * 2009-07-31 2015-08-26 恩多塞特公司 叶酸盐靶向的诊断和治疗
TWI796132B (zh) 2010-02-24 2023-03-11 美商免疫遺傳股份有限公司 葉酸受體1抗體類和免疫共軛物類及彼等之用途
RU2630608C2 (ru) * 2010-11-05 2017-09-11 Морфотек Инк. Рецептор фолиевой кислоты альфа в качестве диагностического и прогностического маркера злокачественных опухолей, экспрессирующих рецептор фолиевой кислоты альфа
KR20130140032A (ko) * 2010-11-12 2013-12-23 엔도사이트, 인코포레이티드 암을 치료하는 방법들
HRP20180358T1 (hr) * 2011-04-01 2018-04-06 Immunogen, Inc. Postupci povećavanja djelotvornosti terapije raka usmjerene protiv folr1
CN103998467B (zh) 2011-07-15 2016-12-14 卫材R&D管理有限公司 抗叶酸受体α抗体及其应用
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
US9200073B2 (en) 2012-08-31 2015-12-01 Immunogen, Inc. Diagnostic assays and kits for detection of folate receptor 1
CN102861020A (zh) * 2012-09-25 2013-01-09 上海交通大学医学院附属仁济医院 叶酸在制备预防大肠腺瘤初发药物中的应用
EP2908818A4 (en) 2012-10-16 2016-07-13 Endocyte Inc CONJUGATES OF DRUG DELIVERY CONTAINING ARTIFICIAL AMINO ACIDS AND METHODS OF USE
US20140154702A1 (en) * 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
ES2883191T3 (es) 2013-08-30 2021-12-07 Immunogen Inc Anticuerpos y ensayos para la detección del receptor 1 de folato
LT3055332T (lt) * 2013-10-08 2020-04-10 Immunogen, Inc. Anti-folr1 imunokonjugato dozavimo režimai
US11162937B2 (en) 2013-11-19 2021-11-02 Purdue Research Foundation Patient selection method for inflammation
JP6246030B2 (ja) * 2014-03-12 2017-12-13 東芝メディカルシステムズ株式会社 病理染色装置及び病理染色方法
HK1255141A1 (zh) 2015-09-17 2019-08-09 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
US11313868B2 (en) 2016-06-14 2022-04-26 Board Of Regents, The University Of Texas System Methods of detecting anti-folic acid antibodies and uses thereof
CN106483282B (zh) * 2016-09-29 2018-08-31 北京世纪沃德生物科技有限公司 一种抗原稳定剂及其制备方法与应用
WO2018098277A1 (en) 2016-11-23 2018-05-31 Eisai R&D Management Co., Ltd Anti-folate receptor alpha antibodies and uses thereof
CN117741149A (zh) * 2024-02-19 2024-03-22 卡秋(江苏)生物科技有限公司 一种用于卵巢癌细胞叶酸受体α的检测试剂盒及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989838A (en) 1992-03-11 1999-11-23 Institute Of Virology, Slovak Academy Of Sciences Immunological methods of detecting MN proteins and MN polypeptides
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
US5846739A (en) * 1995-12-05 1998-12-08 Wisconsin Alumni Research Foundation Immunohistochemical detection assay for carcinoma proliferative status
US6358682B1 (en) 1998-01-26 2002-03-19 Ventana Medical Systems, Inc. Method and kit for the prognostication of breast cancer
AU2001256970C1 (en) * 2000-03-31 2008-07-03 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
CA2461877A1 (en) * 2001-09-28 2003-04-10 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
CN1662251B (zh) 2002-04-19 2012-10-10 恩多塞特公司 佐剂增强的免疫应用
US7910594B2 (en) 2002-05-15 2011-03-22 Endocyte, Inc. Vitamin-mitomycin conjugates
AR042942A1 (es) 2003-01-27 2005-07-06 Endocyte Inc Conjugados de administracion de drogas de union de receptores de vitaminas

Similar Documents

Publication Publication Date Title
JP2008537778A5 (enExample)
Singh et al. TNBC: potential targeting of multiple receptors for a therapeutic breakthrough, nanomedicine, and immunotherapy
Harari et al. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234
Paoluzzi et al. Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
Carthon et al. Epidermal growth factor receptor‐targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis
Tran et al. Survival comparison between glioblastoma multiforme and other incurable cancers
Jiang et al. Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): a multicenter, double-blind, prospective trial
BRPI0916138A2 (pt) "método de tratamento de um sujeito diagnosticado com câncer de mama localmente, kit para tratar câncer de mama metastático em um sujeito humano, uso de um anticorpo antivegf na fabricação de um medicamento para tratar câncer de mama localmente recidivado ou metastático em um sujeito e anticorpo anti-vegf para uso em um método de tratamento de câncer de mama localmente recidivado ou metastático em um sujeito"
RU2007139912A (ru) Способ прогнозирования течения рака на основе количественного анализа клеточного рецептора витамина фолата
JP2008507530A5 (enExample)
NZ601580A (en) Therapeutic methods using anti-cd200 antibodies
WO2005080431A3 (en) Monoclonal antibodies that specifically bind to folate receptor alpha
RU2013106938A (ru) Биомаркеры в плазме крови, предназначенные для комбинированных терапий с использованием бевацизумаба при лечении рака молочной железы
Sahin et al. Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors
Pivot et al. Prognostic impact of the epidermal growth factor receptor levels for patients with larynx and hypopharynx cancer
JP2013520431A5 (enExample)
Abi-Jaoudeh et al. Personalized oncology in interventional radiology
FR2919060B1 (fr) Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal.
Nassim et al. Combining mTOR inhibition with radiation improves antitumor activity in bladder cancer cells in vitro and in vivo: a novel strategy for treatment
Cmelak Current issues in combined modality therapy in locally advanced head and neck cancer
DOP2009000208A (es) Métodos de tratamiento del cáncer mediante administración de combinaciones de il-18 humana
Rendell et al. Targeting tyrosine kinases in ovarian cancer: small molecule inhibitor and monoclonal antibody, where are we now?
JP2013536236A5 (enExample)
WO2008060899A3 (en) Breast cancer screening and treatment methods
WO2011119888A3 (en) N-cadherin: target for cancer diagnosis and therapy